key: cord-0752712-ew5x4ija
authors: Willcox, Alexandra C.; Sung, Kevin; Garrett, Meghan E.; Galloway, Jared G.; Erasmus, Jesse H.; Logue, Jennifer K.; Hawman, David W.; Chu, Helen Y.; Hasenkrug, Kim J.; Fuller, Deborah H.; Matsen IV, Frederick A.; Overbaugh, Julie
title: Detailed analysis of antibody responses to SARS-CoV-2 vaccination and infection in macaques
date: 2022-04-11
journal: PLoS Pathog
DOI: 10.1371/journal.ppat.1010155
sha: 462e86f1527c4ecf793975b96b280142033b5164
doc_id: 752712
cord_uid: ew5x4ija

Macaques are a commonly used model for studying immunity to human viruses, including for studies of SARS-CoV-2 infection and vaccination. However, it is unknown whether macaque antibody responses resemble the response in humans. To answer this question, we employed a phage-based deep mutational scanning approach (Phage-DMS) to compare which linear epitopes are targeted on the SARS-CoV-2 Spike protein in convalescent humans, convalescent (re-infected) rhesus macaques, mRNA-vaccinated humans, and repRNA-vaccinated pigtail macaques. We also used Phage-DMS to determine antibody escape pathways within each epitope, enabling a granular comparison of antibody binding specificities at the locus level. Overall, we identified some common epitope targets in both macaques and humans, including in the fusion peptide (FP) and stem helix-heptad repeat 2 (SH-H) regions. Differences between groups included a response to epitopes in the N-terminal domain (NTD) and C-terminal domain (CTD) in vaccinated humans but not vaccinated macaques, as well as recognition of a CTD epitope and epitopes flanking the FP in convalescent macaques but not convalescent humans. There was also considerable variability in the escape pathways among individuals within each group. Sera from convalescent macaques showed the least variability in escape overall and converged on a common response with vaccinated humans in the SH-H epitope region, suggesting highly similar antibodies were elicited. Collectively, these findings suggest that the antibody response to SARS-CoV-2 in macaques shares many features with humans, but with substantial differences in the recognition of certain epitopes and considerable individual variability in antibody escape profiles, suggesting a diverse repertoire of antibodies that can respond to major epitopes in both humans and macaques. Differences in macaque species and exposure type may also contribute to these findings.

a1111111111 a1111111111 a1111111111 a1111111111 a1111111111

The COVID-19 pandemic has created a pressing need to understand immunity to SARS-CoV-2, both in the setting of vaccination and infection. This has prompted numerous studies in non-human primates (NHPs), which are considered the most relevant animal model for studying many infectious diseases of humans. Various NHP models have been employed to study the immunogenicity and protective efficacy of SARS-CoV-2 vaccine candidates, with most studies using macaque species including rhesus macaques (Macaca mulatta) , cynomolgus macaques (Macaca fascicularis) [8, [24] [25] [26] [27] [28] [29] [30] [31] [32] , and pigtail macaques (Macaca nemestrina) [22, [33] [34] [35] . Some of these models have also been used to study infection and re-infection [35] [36] [37] [38] [39] . In the NHP model, studies typically measure virus neutralizing antibody responses to vaccination or infection. However, no study has investigated the fine binding specificities of both neutralizing and non-neutralizing SARS-CoV-2 antibodies in macaques and how they compare to the human responses they are meant to model.

Coronaviruses such as SARS-CoV-2 enter host cells using their Spike glycoprotein, which is composed of trimeric S1 and S2 subunits. Receptor-binding S1 homotrimers protrude out from the surface of the virion like a crown, giving this family of viruses its name, while the fusion-mediating S2 trimers anchor the protein to the viral membrane. On S1, the receptorbinding domain (RBD) of SARS-CoV-2 Spike protein binds to angiotensin-converting enzyme 2 (ACE2) on host cells [40, 41] . For subsequent membrane fusion to occur, the Spike protein must be cleaved by host cell proteases at the S1/S2 boundary and at an S2' site located just upstream of the fusion peptide (FP) of S2 [42] , leading to substantial conformational changes that likely unmask new epitopes of S2 to immune cells [43] .

Antibodies to SARS-CoV-2 Spike protein are especially interesting as a potential correlate of protection, as they have the capacity to block infection and kill infected cells [44] [45] [46] [47] . There has understandably been great interest in studying neutralizing antibodies against the RBD, given that such antibodies can directly block interaction with host cells. While RBD-directed antibodies indeed contribute disproportionately to neutralization [48] , the majority of the anti-Spike plasma IgG response in convalescent individuals is directed to epitopes outside of the RBD [49, 50] . RBD-directed antibodies are also less likely to maintain activity against future viral strains, given the increasing number of variants of concern that harbor mutations in the RBD and have reduced sensitivity to neutralization by immune plasma [51] . Additionally, growing evidence from studies in humans and animal models indicates that non-neutralizing antibodies play a role in protection [52] [53] [54] .

Previous studies have used Phage-DMS [55] , a tool that combines phage display of linear epitopes with deep mutational scanning, to interrogate the fine binding specificities and escape profiles of binding antibodies against all domains of Spike in infected and vaccinated humans [56, 57] . These studies have shown that infection-induced human polyclonal antibodies consistently bind linear epitopes in the FP and stem helix-heptad repeat 2 (SH-H) epitope regions, with patient-to-patient variability in escape profiles [56] . Comparatively, mRNA vaccination induces a broader antibody response across Spike protein with more consistent escape profiles [57] .

In this study, we built on this foundation by using Phage-DMS to study the binding and escape profiles of antibodies in repRNA-vaccinated pigtail macaques and convalescent (reinfected) rhesus macaques in comparison to mRNA-vaccinated humans and convalescent humans. Our data reveal broad overlap in some major epitopes targeted by both macaques and humans, though neither vaccinated nor convalescent macaques perfectly model the human response. We also find considerable variability in individuals' antibody escape pathways in most epitope regions in both macaques and humans. The broadest responses were seen in vaccinated humans and re-infected rhesus macaques, groups that also share more concordant escape profiles. These results have implications for the interpretation of COVID-19 macaque research studies.

Four groups were included in this study: vaccinated pigtail macaques, vaccinated humans, convalescent (re-infected) rhesus macaques, and convalescent humans ( Table 1 ). The vaccinated macaques received a replicating mRNA (repRNA) vaccine encoding the full-length wildtype (not pre-fusion stabilized) SARS-CoV-2 A.1 lineage Spike protein formulated with a cationic nanocarrier [35, 58] . The vaccine was delivered as a prime-only 25μg (n = 3) or 250μg (n = 6) dose or prime-boost 50μg dose (n = 2), with plasma collected 42 days after the first dose (n = 9) or 14 days after the second dose (n = 2). The vaccinated humans received two doses of the 100μg Moderna mRNA-1273 vaccine encoding the pre-fusion stabilized fulllength SARS-CoV-2 A.1 lineage Spike protein and formulated with a lipid nanoparticle.  Serum was collected from human vaccinees 36 days after the first dose (7 days after the second  dose). The convalescent macaques were depleted of CD4+ T cells, CD8+ T cells, CD4+ and  CD8+ T cells, or neither as part of a previous study. They were infected twice with SARS-CoV-2 , with infections spaced six weeks apart and serum collected 56 days after the first infection (14 days after the second infection). The T cell depleted animals were not excluded based on a detailed analysis of the humoral response in these macaques, which suggested that neither CD4+ nor CD8+ T cells were critical for the development of anamnestic antibody responses, neutralizing antibodies, or protection from re-infection [39] . The convalescent humans were naturally infected once with SARS-CoV-2 and exhibited mild disease, with a median of 67 days between symptom onset and sample collection. Details of individual participants are available in S1 Table.

To compare which regions of Spike protein are recognized by human and macaque antibodies, we examined the enrichment of wildtype peptides by antibodies from each individual ( Fig  1A) . Broadly speaking, binding was observed in the NTD, CTD, FP, and stem helix-HR2 epitope regions as reported previously in human studies [56, 57] . Epitope regions (shown as different colors on Fig 1) were defined as previously [57] : 

Macaque antibodies to SARS-CoV-2 Spike to these defined regions, we noted that one convalescent rhesus macaque appeared to weakly recognize an epitope at the beginning of the S2 subunit (amino acid 686-710, Fig 1A) .

In general, we did not detect responses in the RBD because many epitopes in this region are known to be conformational, and Phage-DMS only has the power to detect epitopes that include linear sequences. Epitopes in the RBD have been extensively detailed elsewhere [59, 60] . However, we did detect strong binding to an RBD epitope in some vaccinated pigtail macaques (Fig 1A) . This same region was enriched in samples from before vaccination in four of the five pigtail macaques with baseline samples available (S2 Fig). Pre-infection serum from the twelve rhesus macaques did not show such a consistent response, though a few individuals did show strong enrichment of certain peptides (S2 Fig). Because these responses were present prior to vaccination with SARS-CoV-2 Spike or infection with SARS-CoV-2, we did not investigate them further as part of this study. These findings are likely the result of prior exposure to a different coronavirus, as has been documented for human infections.

To quantify differences in the epitopes targeted by different groups, the enrichment of wildtype peptides was summed across each epitope region for every individual. Because the main research question is whether responses in macaques model those in humans, two comparisons were performed: vaccinated macaques vs. vaccinated humans and convalescent macaques vs. convalescent humans (Fig 2) .

In concordance with a qualitative assessment of the enrichment heatmap in Fig 1A, vaccinated humans preferentially recognized the following epitope regions compared to vaccinated macaques: NTD (Mann-Whitney p � 0.01), CTD-C' (p � 0.0001), and FP (p � 0.05) (Fig 2A) . Meanwhile, convalescent macaques recognized the following epitope regions more than convalescent humans: CTD-N' (p � 0.01), pre-FP (p � 0.001), and post-FP (p � 0.01) ( Fig 2B) . All groups consistently recognized the SH-H epitope region (Fig 2) . While vaccination appeared to induce a stronger response against HR2 than infection (Fig 1A) , there were no significant differences in response driven by species (Fig 2) . Within each group of macaques (vaccinated and convalescent), subgroups received slightly different treatments (S1 Table) , so similar analyses were performed comparing these subgroups; no comparisons were significant at a threshold of p = 0.05 (Kruskal-Wallis test, S3 Fig) . Taken together, these findings indicate: 1) vaccinated humans were the only group to consistently recognize peptides from both the NTD and CTD-C' epitope regions, which are in close physical proximity to one another ( Fig 1B) ; 2) convalescent humans had a limited response to the CTD-N'; 3) compared to other groups, convalescent macaques had a notably more robust response to regions upstream and downstream of the main FP epitope region; 4) vaccinated macaques did not recognize the FP as strongly as other groups; and 5) vaccination seemed to induce a stronger response against HR2 than infection in both macaques and humans. These findings may also be explained by other differences between the vaccinated and convalescent groups, including the number, dose, and type of exposures.

To assess differences in the binding characteristics of human and macaque antibodies on a more granular level, we next examined the mutations in Spike that reduced antibody binding in each epitope region of interest. Because the antibody escape pathways for vaccinated humans have been described previously [57] , we did not examine the NTD and CTD-C', which are exclusively recognized by this group. Instead, we focused on comparing escape profiles between groups in the following epitope regions: CTD-N', FP, and SH-H. We first represent the data as scaled differential selection values in logo plot form, as commonly shown in previous studies. Importantly, scaled differential selection is highly correlated with peptide binding as measured by competition ELISA [55] . To summarize the data represented by the logo plots by group, summed differential selection values across each epitope region were also calculated. This metric represents the overall magnitude of escape at each locus regardless of the specific amino acid substitution, with negative values indicating a decrease in binding compared to the wildtype amino acid, and positive values indicating enhanced binding (see "Materials and Methods"). Finally, escape similarity scores were calculated between pairs of individuals to quantify similarity in escape profiles (see "Materials and Methods" and S4 Fig).

Vaccinated macaques, vaccinated humans, and convalescent macaques recognized peptides in the CTD-N' (AA 526-593), whereas convalescent humans generally did not ( Fig 2B) . Within this epitope region, the individual escape profiles showed notable variability both within and between groups (S5 Fig). For example, across all groups, some individuals showed relatively high sensitivity to mutations between sites 558-567, while others had a response focused more downstream around AA 577-586. There was also substantial variability in which loci in the CTD-N' had the highest relative magnitude of escape, and sometimes even in the directionality of scaled differential selection at a given locus. For example, some individuals had antibodies that bound mutated peptides better than wildtype at AA 555 (e.g., convalescent macaque 353) while others exhibited reduced binding to mutated peptides (e.g., convalescent macaque 358). The same was true for site 560 (e.g., vaccinated humans M24 and M26 exhibited improved and disrupted binding to mutated peptides, respectively).

To summarize the trends observed in the individual findings, we calculated summed differential selection values for each individual at each site and generated boxplots by group (Fig 3A) . In addition to the aforementioned regions of escape common to all groups, convalescent macaques also showed considerable escape between AA 529-535, with vaccinated macaques also showing a less consistent response in this area (Figs 3A and S5). The complexity and variability of the escape pathways also prompted us to quantify the similarity in escape between and within groups. Escape similarity scores largely corresponded to areas of high magnitude of escape. Sites with low-magnitude summed differential selection values indicate loci where mutations have no notable impact,

Macaque antibodies to SARS-CoV-2 Spike and therefore those escape profiles reflect fluctuations in peptide enrichments due to noise, which drives a lower escape similarity score at those sites ( Fig 3A, lower panel) . At some sites (e.g., 560, as described above), low scores were also the result of some samples showing negative differential selection and others showing positive differential selection, a comparison that was assigned the highest cost in our escape similarity score algorithm.

To test the similarity of escape profiles across the CTD-N' epitope region, escape similarity scores were aggregated across the region and computed both within and between groups. These are shown as boxplots, with each point representing a pairwise comparison between individual samples (Fig 3B) . For example, every vaccinated macaque was compared to every other vaccinated macaque (a within-group comparison) and to every vaccinated human (a between-group comparison). We included a comparison of convalescent macaques and vaccinated humans, given visual similarities between their patterns of escape ( Fig 3A) . Convalescent macaques showed the highest within-group similarity in escape profiles, meaning their escape profiles were more consistent than those of the vaccinated macaques or vaccinated humans ( Fig 3B) . Between-group escape similarity scores were on par with the within-group scores for the vaccinated macaques and humans, indicating that although there was substantial variability in individual profiles, this was not driven by sample groups.

Escape profiles were examined in the FP epitope region (AA 805-835) for the three groups that showed significant wildtype enrichment in this area: vaccinated humans, convalescent Within-and between-group region-wide escape similarity scores, with each point representing a pairwise comparison between two samples. The box represents median and interquartile range (IQR), the lower whisker represents the lowest data point above Q1-1.5IQR, and the upper whisker represents the highest data point below Q3+1.5IQR. The contribution of a site's score to the total escape similarity score is weighted based on its relative contribution to the summed differential selection values across the region. P values are not computed due to lack of independence between data points.

https://doi.org/10.1371/journal.ppat.1010155.g003

Macaque antibodies to SARS-CoV-2 Spike macaques, and convalescent humans. As in the CTD-N', overall there was variability in individual escape profiles, though the convalescent macaques showed a more consistent pattern of escape than other groups (S6 Fig). Within the FP, most sites of escape fell between AA 811-825 for all groups (Fig 4A) . The convalescent macaques again exhibited the highest escape similarity scores (Fig 4B) . The median within-group escape similarity scores in the FP were on par with those in the CTD-N' (Fig 3B) , indicating approximately equal variability in antibody escape in these epitope regions. The between-group escape similarity scores were generally similar to each other and to the human within-group scores (Fig 4B) .

All four groups consistently recognized peptides spanning the SH-H epitope region (AA 1135-1170). Major sites of escape were located between AA 1145-1158 for all groups (Fig 5A) . The individual logo plots in the SH-H suggested a consistent response among vaccinated humans and convalescent macaques, with more variability in the remaining groups (S7 Fig) . This finding is supported by the within-group escape similarity scores for those groups trending higher across the epitope region (Figs 5A lower panel and 5B). The median epitope regionwide escape similarity scores for vaccinated humans and convalescent macaques were also higher in the SH-H than in the CTD-N' or FP, confirming a more concordant response. The median between-group escape similarity score for vaccinated humans and convalescent macaques was on par with their median within-group scores, indicating that the escape profile of a vaccinated human looks as similar to that of a convalescent macaque as it does to another vaccinated human (Fig 5B) . The similarity between these two groups was higher than the similarity between convalescent macaques and humans, as well as between vaccinated macaques and humans (Fig 5B) . Despite this overall trend, two vaccinated humans had more unique escape profiles (S7 Fig, M26 and M19) and are responsible for a cluster of lower-similarity outlier points (Fig 5B, " Vaccinated Humans" and "Conv. Mac. vs. Vacc. Hum.").

The pairwise comparison between participant 352 (a convalescent macaque) and M21 (a vaccinated human) generated an escape similarity score closest to the median for all comparisons between these groups. Logo plots for these individuals are shown in Fig 5C as 

In addition to the epitope regions described above, the convalescent macaques strongly recognized the pre-FP and post-FP, which were not targeted by human antibody responses (S8 Fig). Escape profiles in the pre-FP appeared highly consistent among individual macaques, with major sites of escape at AAs 795, 798, 800, and 802. Profiles were more variable in the post-FP, likely due in part to low enrichment of wildtype peptides in this epitope region for some individuals (S8 Fig). 

It was notable that the vaccinated humans and convalescent macaques showed the most similarity in escape profiles across all epitope regions, most strikingly in the SH-H. Thus, we also asked whether they showed similarity in the epitopes they targeted by comparing the enrichment of wildtype peptides in these groups in each epitope region (S9 Fig). Vaccinated humans recognized the following epitope regions more strongly than convalescent macaques: NTD (Mann-Whitney p � 0.0001), CTD-C' (p � 0.0001), and HR2 (p � 0.001). Convalescent macaques preferentially recognized the pre-FP (p � 0.0001) and post-FP (p � 0.001) epitope regions. This suggests some diversity in the epitopes targeted, but similarity of antibody escape patterns within epitopes targeted by both groups. 

Macaque antibodies to SARS-CoV-2 Spike

In this study, we aimed to assess whether the antibody binding specificities to SARS-CoV-2 Spike in macaques are a useful model for the human response. Our results indicate important similarities between macaques and humans; for example, both have antibodies that recognize major epitopes in the CTD, FP, and SH-H. However, many differences are also apparent, with some groups showing responses to unique epitopes, such as two physically proximal epitopes in the NTD and CTD that are recognized by antibodies from vaccinated humans but not macaques. Additionally, epitope regions flanking the FP were recognized by antibodies from convalescent macaques, while antibodies from convalescent humans did not recognize the flanking regions but showed a strong response within the FP itself. We found considerable diversity in the pathways of escape between individuals, and this was not specific to either macaques or humans, suggesting a diverse repertoire of antibodies that can respond to the major epitopes in both groups. Overall, these results suggest that macaques and humans share recognition of certain major epitopes. The differences that exist could be due to species (macaque vs. human), but could also be influenced by differences in the specific type and number of exposures to antigen in each group.

Other studies have characterized human monoclonal antibodies against some of the epitopes we report here, many of them with neutralizing or other activities. As previously reported by our group [57] , we found that antibodies from vaccinated humans bound peptides spanning a 30 amino acid segment at the C-terminus of the NTD. Interestingly, most if not all neutralizing human mAbs targeting the SARS-CoV-2 NTD to date have been shown to target a single supersite on the "tip" of Spike, distinct from the epitope we detected at the C-terminus [49, [61] [62] [63] [64] [65] [66] [67] . An NTD mAb with Fc effector function [54], as well as several NTD mAbs that enhance infection in vitro [62, 68] , also bind sites upstream of the C-terminal epitope. Therefore, future studies are warranted to investigate the function of antibodies binding the new NTD epitope detected by Phage-DMS. In the CTD, we detected broad antibody binding, with vaccinated macaques, vaccinated humans, and convalescent macaques enriching peptides in the CTD-N' epitope region, and vaccinated humans also recognizing peptides spanning the remainder of this domain (CTD-C'). Polyclonal antibodies targeting sites within the CTD-N' and CTD-C' have been isolated from human sera and shown to have neutralizing activity [69] . Interestingly, the neutralizing epitope on the CTD-C' (AA 625-636) [69] is physically adjacent to the NTD epitope we describe (AA 285-305), raising the possibility that a conformational epitope extending to the NTD is recognized by neutralizing antibodies from vaccinated humans. Depleting human serum of FP-binding antibodies reduced its neutralization capacity [70] ; these antibodies are of high interest, both due to their potential to block membrane fusion, and given the high sequence conservation among the FPs of diverse coronaviruses [71, 72] . We found that convalescent rhesus macaque sera strongly recognized the pre-and post-FP epitope regions, but to our knowledge, functional antibodies against these regions have not been previously described. Finally, the SH-H epitope region we describe is in the stem helix, a region known to be highly conserved across coronaviruses. Broadly neutralizing [73] [74] [75] stem helix antibodies have been isolated and suggest an avenue for rational design of a pan-coronavirus vaccine. Interestingly, a mAb raised against the MERS-CoV stem region protected mice against SARS-CoV-2 challenge, despite having no neutralizing activity against SARS-CoV-2 in vitro [76] . The detection of broad antibody binding across Spike supports the continued investigation of non-RBD epitopes, which remain understudied. Some of the epitopes we describe may also be the target of non-neutralizing Fc-effector antibodies [77] , and/or antibodies that enhance infection via Fc-independent [68] or Fc-dependent [78] mechanisms. This latter concept may be important in the pathogenesis of COVID-19, though this remains speculative.

Previous work elucidated that pathways of antibody escape to SARS-CoV-2 Spike protein can be quite variable in convalescent humans, with vaccination inducing a more consistent response [57] . In the current study, we found considerable variability in escape profiles in the FP and CTD-N' in both macaques and humans, though the convalescent rhesus macaques had more concordant escape profiles than other groups. Variability in escape patterns suggests that a diversity of antibodies are targeting these epitopes. Intra-species germline diversity in immunoglobulin genes may help explain why individuals with similar exposures often mount distinct responses [79, 80] . On the other hand, escape profiles were more consistent in the SH-H, where the responses of convalescent macaques and vaccinated humans appeared to converge. This conservation of response suggests that highly similar antibodies are dominating the antibody repertoire against this epitope. Convergent antibody responses to SARS-CoV-2 have been reported within human populations [81] [82] [83] , and our findings here suggest that antibodies from different species may also be able to converge on the same "public" antibody repertoires in a functional sense, despite genetic differences. While a shared escape profile among individuals could suggest that viral escape mutations are more likely to emerge on a population level, another factor to consider is the effect of the mutations on viral fitness. Key domains of the S2 subunit (such as the SH-H epitope) have essential functions and high sequence conservation, suggesting a low tolerance for mutation and thus for escape. Indeed, previous work determined that sites of escape identified by Phage-DMS are not typically mutated at a high frequency in circulating strains of SARS-CoV-2 [56] .

While our focus was on understanding how macaques and humans respond to a similar exposure (i.e., vaccination or infection), we also noted similarities in response between reinfected macaques and vaccinated humans. These groups both exhibited the broadest recognition across Spike, although the epitope regions they targeted were somewhat different. As described above, these groups also had highly similar antibody escape profiles in the SH-H. The vaccinated humans and re-infected macaques both received two exposures to high doses of antigen. It is plausible that re-exposure directed initially diverse antibodies to converge on a more focused response in both scenarios. While it is known that vaccination and infection induce distinct humoral responses against Spike [57, 84, 85] , our data suggest that a second exposure may generate antibodies that better match the vaccine-induced response.

This study had several limitations. Because the Phage-DMS library displays peptides 31AA in length, discontinuous or conformational epitopes are not readily detected using this method. Additionally, epitopes that may normally be glycosylated are exposed for antibody binding in Phage-DMS. There also are known germline-encoded differences in the properties of immunoglobulin subclasses and Fc receptors between macaques and humans, leading to differences in antibody function that cannot be assayed using Phage-DMS [86] . Additionally, our sample set includes variables that limit our ability to draw conclusions about species-specific (macaque vs. human) differences in antibody response. The vaccinated macaques and humans both received RNA vaccines encoding full-length Spike protein, but there were differences in vaccine technology, including: 1) the use of mRNA in the human vaccine vs. repRNA in the macaque vaccine, 2) the stabilization of Spike in its pre-fusion state in the human vaccine, 3) the dosage and number of doses delivered, and 4) the formulation used to deliver the RNA. Despite these differences, we found commonalities in some of the epitopes targeted by antibodies from both groups. The convalescent rhesus macaques also underwent T cell depletion as part of another study, which may have altered the epitope specifity of their antibodies, although we did not find significant differences between depleted and control animals in our analysis ( S3 Fig). Additionally, the convalescent rhesus macaques were experimentally infected twice with high titers of virus, compared to the convalescent humans who were naturally infected once. This important discrepancy could be the reason why the response in re-infected macaques aligned more closely with vaccinated humans than convalescent humans. Studies of

Macaque antibodies to SARS-CoV-2 Spike re-infected humans would help address this possibility. Finally, we found pre-existing antibody responses in both groups of macaques. Many of our human samples also likely contain crossreactive antibodies from prior endemic coronavirus infections. These pre-existing responses are difficult to control for but may have influenced our results.

Our findings suggest that while vaccinated and convalescent macaques and humans share recognition of some major epitopes, each group has a unique antibody binding profile. Antibody escape profiles suggest a diversity of individual responses to most epitopes. Important avenues for future study include comparing macaque and human responses to the RBD and evaluating species differences in antibody function. Continued investigation of immunogenic epitopes in conserved regions of Spike is also warranted to inform the development of immunity that is more robust in the face of viral escape.

For the vaccinated pigtail macaques, all procedures were approved by the University of Washington's Institutional Animal Care and Use Committee (IACUC) (IACUC #4266-14). For the convalescent rhesus macaques, all procedures were performed in accordance with Animal Study Proposal RML 2020-046-E approved by the IACUC of Rocky Mountain Laboratories (National Institutes of Health). For the vaccinated humans, all participants provided written informed consent. Because samples were de-identified, this study was approved by the Fred Hutchinson Cancer Research Center Institutional Review Board as non-human subjects research. For the convalescent humans, electronic informed consent was obtained for all participants. This research was approved by the University of Washington Institutional Review Board (IRB number STUDY00000959).

Vaccinated pigtail macaques. Plasma was collected from 11 pigtail macaques immunized with a replicating RNA (repRNA) vaccine expressing full-length SARS-CoV-2 Spike protein.

A subset of these animals was previously described [35] . All animals were housed at the Washington National Primate Research Center (WaNPRC), an accredited facility of the American Association for the Accreditation of Laboratory Animal Care International (AAALAC). Individual macaques received the vaccine by intramuscular injection in either a Lipid InOrganic Nanoparticle (LION) [35] or a Nanostructured Lipid Carrier (NLC) [58] formulation, delivered in a single priming dose of 25μg (n = 3) or 250μg (n = 6) or in a prime-boost regimen with 50μg doses spaced 4 weeks apart (n = 2). All samples were collected 6 weeks post-prime immunization. A subset of these animals also previously received an experimental hepatitis B vaccine as part of another study (n = 5).

Convalescent rhesus macaques. Serum was collected from 12 rhesus macaques housed at the Rocky Mountain Laboratories (National Institutes of Health [NIH]), 14 days after the second of two SARS-CoV-2 infections spaced 42 days apart. The SARS-CoV-2 isolate used for infection was nCoV-WA1-2020 (MN985325.1), which was provided by the Centers for Disease Control and Prevention and propagated as described previously [39] . This isolate came from a COVID-19 patient in Washington state in January 2020 and therefore represents an ancestral strain, prior to the emergence of variants. Prior to infection, macaques were variably depleted of CD4+ T cells, CD8+ T cells, CD4+ and CD8+ T cells, or neither, as part of another study. Details of macaque treatment and regulatory approvals are as published previously [39] .

Vaccinated humans. We obtained serum from 15 individuals who received two 100μg doses of the Moderna mRNA-1273 vaccine as part of a phase I clinical trial (NCT04283461) [87] . Phage-DMS results from these samples were reported previously [57] . Only samples from individuals aged 18-55 years were included in the current study to better match the young age range of the macaques. Convalescent humans. Plasma was collected from 12 individuals post-mild COVID-19 illness as part of the Hospitalized or Ambulatory Adults with Respiratory Viral Infections (HAARVI) study in Seattle, WA. The date of symptom onset for these individuals ranged from February-March 2020, representing infections with early circulating strains of SARS-CoV-2. Phage-DMS results from these samples were reported previously [56, 57] . Again, the sample set was restricted to only include individuals aged 18-55 years to better match other sample groups.

All plasma and sera were heat inactivated at 56˚C for 1 hour prior to use. Full details of all samples are available in Tables 1 and S1 .

The experimental protocol was performed exactly as described previously [56] . Briefly, an oligonucleotide pool was synthesized that contains sequences coding for peptides of 31 amino acids that tile along the length of the Wuhan-Hu-1 Spike protein sequence [88] in 1 amino acid increments. For each peptide with the wildtype sequence, 19 variations were included that have a single mutation at the middle amino acid, resulting in a total library size of 24,820 unique sequences. The oligonucleotide pool was cloned into T7 phage, followed by amplification of the phage library; this step was performed twice independently to generate biological duplicate phage libraries. The phage library was incubated with a serum or plasma sample, then bound antibody-phage complexes were immunoprecipitated using Protein A and Protein G Dynabeads (Invitrogen). Bound phage were lysed, and DNA was amplified by PCR and cleaned prior to sequencing on an Illumina MiSeq or HiSeq 2500 with single end reads. Demultiplexing and read alignment were also performed as described previously [57] .

Biological replicates were analyzed in parallel to assess reproducibility of results. For simplicity, results from only one biological replicate are shown and described, with the same figures generated with the second biological replicate available to view online at https://github.com/ matsengrp/phage-dms-nhp-analysis. Within each biological replicate, "in-line" technical replicates were run for some samples. In these cases, the technical replicate with the highest mapped read count was selected for analysis.

The enrichment of wildtype peptides was calculated as described previously to quantify the proportion of each peptide in an antibody-selected sample relative to the proportion of that peptide in the input phage library [55] . On enrichment plots, the locus of each peptide is defined by its middle amino acid. Enrichment values of wildtype peptides were summed across epitope regions of interest for statistical comparisons between groups ("Summed WT enrichment" on figures).

The effect of a mutation on antibody-peptide binding was quantified as "differential selection," which is the log fold change in the enrichment of a mutation-containing peptide compared to the wildtype peptide. This number is multiplied by the average of the wildtype peptide

Macaque antibodies to SARS-CoV-2 Spike enrichments at that site and its two adjacent sites to get a "scaled differential selection" value, as described previously [57] . The enrichment values of the adjacent wildtype peptides are included in this calculation to make the analysis less susceptible to noise. Negative differential selection values represent reduced binding compared to wildtype, while positive differential selection values indicate that the mutation enhanced binding. "Summed differential selection" is the sum of the 19 scaled differential selection values for all mutations at a site, and gives a sense of the overall magnitude of escape at that site.

The comparison of two escape profiles is quantified by an escape similarity score computed in the framework of an optimal transport problem [89] ; this algorithm was described in detail at https://matsengrp.github.io/phippery/esc-prof.html. An overview of the method is shown in S4 Fig. Escape profiles are commonly portrayed as logo plots using scaled differential selection values (S4A Fig). At each site, escape data in logo plot form can instead be represented as binned distributions, with each mutation making some contribution to the total amount of escape at that site based on its scaled differential selection value (S4B Fig). For each site, an optimal transport problem computes the most efficient way to transform one individual's escape distribution into that of a different individual (S4C Fig) . The cost to "exchange" amino acid contributions between profiles is based on the similarity between the amino acids being exchanged, as defined by the BLOSUM62 matrix [90] . More "movement" between dissimilar amino acids drives up the total cost of the transport; therefore, a higher cost indicates less similar profiles. Escape similarity scores are the inverse of the total cost of transforming one profile into another. Scores were calculated between pairwise combinations of individuals to compare escape profile variability within and between sample groups.

The structure of a SARS-CoV-2 Spike glycoprotein monomer in the closed state (PDB 6XR8) was examined to visualize epitope regions [91] . Coloring was added using UCSF ChimeraX-1.2.5, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with support from National Institutes of Health R01-GM129325 and the Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases [92] . Boxplots are used to summarize summed wildtype enrichment values, summed differential selection values, and similarity scores within a sample group. For all boxplots, the box represents the median and interquartile range (IQR), the lower whisker represents the lowest data point above Q1-1.5IQR, and the upper whisker represents the highest data point below Q3+1.5IQR.

All analyses were performed in RStudio version 1.3.1093, Python version 3.6.12, GraphPad Prism version 9.0.1, and the phip-flow and phippery software suite (https://matsengrp.github. io/phippery/). The phip-flow tools perform read alignment using Bowtie2 [93] in a Nextflow

Macaque antibodies to SARS-CoV-2 Spike [94] pipeline script. The escape profile comparisons are done with phippery in Python 3.6.12 and depend on the NumPy [95] , pandas [96, 97] , xarray [98] , POT [99] , and biopython [100] packages.

Supporting information S1 Table. The optimal transport solution to transform one profile to the other is computed, where the cost to "exchange" an amino acid contribution in Profile 1 to an amino acid contribution in Profile 2 is derived from the BLOSUM62 matrix. For the purposes of the schematic, the number of dollar signs associated with each line denotes the relative cost of each move (i.e., more dollar signs = more costly = moving between amino acids that are less similar). (D) To quantify similarity between profiles, an escape similarity score is calculated as the inverse of the total cost to perform the transformation. For more details, see https://matsengrp.github.io/ phippery/esc-prof.html. Created with BioRender.com. (TIF)

Macaque antibodies to SARS-CoV-2 Spike 

Macaque antibodies to SARS-CoV-2 Spike

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

ChA-dOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

Development of an inactivated vaccine candidate for SARS-CoV-2

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques

Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses

Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques

A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques. Vaccines (Basel)

Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques

SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques

A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs

Self-Assembling Nanoparticle Vaccines Displaying the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Responses in Rhesus PLOS PATHOGENS Macaque antibodies to SARS-CoV-2 Spike PLOS Pathogens

A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques

Adjuvanting a subunit COVID-19 vaccine to induce protective immunity

COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates

Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates

Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines

Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate

A Thermostable mRNA Vaccine against COVID-19

SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates

Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection

Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates

Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice

Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19

Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models

Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2

Immunogenicity of primeboost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques

An Alphavirusderived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in PLOS PATHOGENS Macaque antibodies to SARS-CoV-2 Spike PLOS Pathogens

Phage-DMS: A Comprehensive Method for Fine Mapping of

High-resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies

Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein after infection and/or vaccination. Elife. 2022:e73490

A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika

Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies

A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain

A neutralizing human antibody binds to the Nterminal domain of the Spike protein of SARS-CoV-2

In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Structure-based development of human antibody cocktails against SARS-CoV-2

Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies

Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients

Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients

Coronavirus membrane fusion mechanism offers a potential target for antiviral development

Characterization of a highly conserved domain within the severe acute respiratory syndrome coronavirus spike protein S2 domain with characteristics of a viral fusion peptide

A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection

Broad betacoronavirus neutralization by a stem helix-specific human antibody

Structural Basis and Mode of Action for Two Broadly Neutralizing Antibodies Against SARS-CoV-2 Emerging Variants of Concern

Stabilized coronavirus spike stem elicits a broadly protective antibody

Dissecting antibody-mediated protection against SARS-CoV-2

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

Immunoglobulin germline gene variation and its impact on human disease

Structure and Diversity of the Rhesus Macaque Immunoglobulin Loci through Multiple De Novo Genome Assemblies. Front Immunol

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals

Human B Cell Clonal Expansion and Convergent Antibody Responses to SARS-CoV-2

Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection

SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2

Mind the Gap: How Interspecies Variability in IgG and Its Receptors May Complicate Comparisons of Human and Non-human Primate Effector Function

An mRNA Vaccine against SARS-CoV-2-Preliminary Report

A new coronavirus associated with human respiratory disease in China

Histoire de l'Acadé mie Royale des Sciences de Paris, avec les Mé moires de Mathématique et de Physique pour la même année

Amino acid substitution matrices from protein blocks

Distinct conformational states of SARS-CoV-2 spike protein

Structure visualization for researchers, educators, and developers

Fast gapped-read alignment with Bowtie 2

Nextflow enables reproducible computational workflows

Array programming with NumPy

The pandas development team. pandas-dev/pandas: Pandas

Data Structures for Statistical Computing in Python

N-D labeled Arrays and Datasets in Python

Biopython: freely available Python tools for computational molecular biology and bioinformatics

We thank Caitlin Stoddard for helpful guidance on the analysis and interpretation of our results. We are also grateful to Cassie Sather and others at the Genomics core facility for assistance with sequencing. We thank Lisa Jackson (Kaiser Permanente), Chris Roberts, Catherine Luke, and Rebecca Lampley [National Institute of Allergy and Infectious Diseases (NIAID), NIH] for assistance obtaining the mRNA-1273 phase 1 trial vaccine samples (NCT04283461). We thank all volunteers in the phase 1 trial, as well as all research participants and study staff of the Hospitalized or Ambulatory Adults with Respiratory Viral Infections (HAARVI) study, without whom this work would not be possible.

Macaque antibodies to SARS-CoV-2 Spike